Published in Thorax on April 01, 2005
Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD. Int J Chron Obstruct Pulmon Dis (2008) 1.46
A randomized controlled trial to assess the efficacy of tiotropium in Canadian patients with chronic obstructive pulmonary disease. Can Respir J (2007) 1.40
Randomized phase II trial of inhaled budesonide versus placebo in high-risk individuals with CT screen-detected lung nodules. Cancer Prev Res (Phila) (2010) 1.06
Evaluation of the sustaining effects of Tai Chi Qigong in the sixth month in promoting psychosocial health in COPD patients: a single-blind, randomized controlled trial. ScientificWorldJournal (2013) 0.83
Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med (2001) 27.83
Lung volumes and forced ventilatory flows. Report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official Statement of the European Respiratory Society. Eur Respir J Suppl (1993) 20.55
A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis (1992) 15.92
Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (2003) 10.97
Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA (1994) 10.46
Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 10.05
Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force. Eur Respir J (1995) 7.03
Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2000) 5.49
A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J (2002) 4.68
Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med (1999) 4.65
Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J (2003) 4.20
Course and prognosis of chronic obstructive lung disease. A prospective study of 200 patients. N Engl J Med (1969) 4.09
Impact of COPD in North America and Europe in 2000: subjects' perspective of Confronting COPD International Survey. Eur Respir J (2002) 4.01
Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: a randomised controlled trial. Lancet (1999) 3.90
Toward a consensus definition for COPD exacerbations. Chest (2000) 3.70
Midthigh muscle cross-sectional area is a better predictor of mortality than body mass index in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 3.69
Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J (2002) 3.66
Handling uncertainty in cost-effectiveness models. Pharmacoeconomics (2000) 3.37
Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med (1997) 3.31
The economic burden of COPD. Chest (2000) 3.21
Office spirometry significantly improves early detection of COPD in general practice: the DIDASCO Study. Chest (2004) 3.09
Not 15 but 50% of smokers develop COPD?--Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med (2003) 3.05
Early detection of COPD in a high-risk population using spirometric screening. Chest (2001) 2.90
Impact of preventing exacerbations on deterioration of health status in COPD. Eur Respir J (2004) 2.80
Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2002) 2.63
The 6-min walk distance: change over time and value as a predictor of survival in severe COPD. Eur Respir J (2004) 2.63
The costs of treating COPD in the United States. Chest (2001) 2.43
Spirometry in primary care practice: the importance of quality assurance and the impact of spirometry workshops. Chest (1999) 2.42
Pharmacoeconomic evaluation of COPD. Chest (2000) 2.35
The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med (2002) 2.29
An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax (1999) 2.15
Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax (2003) 2.11
Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation. Chest (2002) 2.02
Measurement of symptoms, lung hyperinflation, and endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 2.01
A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med (1999) 1.99
Economic analysis of the Confronting COPD survey: an overview of results. Respir Med (2003) 1.93
Long-term effects of outpatient rehabilitation of COPD: A randomized trial. Chest (2000) 1.91
Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med (2000) 1.89
Pharmacoeconomic evaluation of acute exacerbations of chronic bronchitis and COPD. Chest (2002) 1.83
Using quality of life to predict hospitalization and mortality in patients with obstructive lung diseases. Chest (2002) 1.83
Validity and reliability of the St George's Respiratory Questionnaire after adaptation to a different language and culture: the Spanish example. Eur Respir J (1996) 1.72
Validity of spirometric testing in a general practice population of patients with chronic obstructive pulmonary disease (COPD). Thorax (2003) 1.70
Maintenance after pulmonary rehabilitation in chronic lung disease: a randomized trial. Am J Respir Crit Care Med (2002) 1.61
Analysis of clinical methods used to evaluate dyspnea in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 1.59
Costs of COPD in Sweden according to disease severity. Chest (2002) 1.52
Do GOLD stages of COPD severity really correspond to differences in health status? Eur Respir J (2003) 1.49
Randomised study of n of 1 trials versus standard practice. BMJ (1996) 1.41
[Recurrent respiratory infections in patients with chronic obstructive bronchitis: medical treatment and costs]. Rev Mal Respir (1996) 1.41
Acute exacerbation of COPD: factors associated with poor treatment outcome. Chest (2000) 1.41
Costs of chronic bronchitis and COPD: a 1-year follow-up study. Chest (2003) 1.37
A comparison of the original chronic respiratory questionnaire with a standardized version. Chest (2003) 1.31
Resource use and risk factors in high-cost exacerbations of COPD. Respir Med (2004) 1.28
Scaling back goals and recalibration of the affect system are processes in normal adaptive self-regulation: understanding 'response shift' phenomena. Soc Sci Med (2000) 1.28
Death stories: acute exacerbations of chronic obstructive pulmonary disease. Qual Health Res (2001) 1.27
One-year cost-effectiveness of tiotropium versus ipratropium to treat chronic obstructive pulmonary disease. Eur Respir J (2004) 1.26
Chronic obstructive disease of small airways. Ann Intern Med (1971) 1.19
Methods to analyse cost data of patients who withdraw in a clinical trial setting. Pharmacoeconomics (2003) 1.14
Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ (2003) 1.08
Assessing the reversibility of airway obstruction. Chest (1998) 1.04
Association between health-related quality of life and consultation for respiratory symptoms: results from the DIMCA programme. Eur Respir J (1998) 0.96
Longitudinal trends in exercise capacity and health status after pulmonary rehabilitation in patients with COPD. Respir Med (2003) 0.96
Capitation, managed care, and chronic obstructive pulmonary disease. Am J Respir Crit Care Med (1998) 0.94
An economic overview of chronic obstructive pulmonary disease. Pharmacoeconomics (2001) 0.90
Economic analysis of respiratory rehabilitation. Chest (1997) 0.89
Current and future medical costs of asthma and chronic obstructive pulmonary disease in The Netherlands. Respir Med (1999) 0.89
[Reliability of chronic obstructive pulmonary disease diagnosis by primary care physicians and pneumologists in Spain. Predictive factors]. Arch Bronconeumol (2003) 0.89
Interpretation of change and longitudinal validity of the quality of life for respiratory illness questionnaire (QoLRIQ) in inpatient pulmonary rehabilitation. Qual Life Res (2003) 0.85
The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee. Eur Respir J (2001) 0.83
Cost-effectiveness of salmeterol in patients with chronic obstructive pulmonary disease: an economic evaluation. Respir Med (2003) 0.80
[Socioeconomic relevance of acute exacerbations of chronic bronchitis in the Federal Republic of Germany. A prospective cost of illness study]. Dtsch Med Wochenschr (2001) 0.76
Long-range correlations of serial FEV1 measurements in emphysematous patients and normal subjects. J Appl Physiol (1985) (1998) 0.76
Standardisation of spirometry. Eur Respir J (2005) 48.20
General considerations for lung function testing. Eur Respir J (2005) 7.99
Standardisation of the single-breath determination of carbon monoxide uptake in the lung. Eur Respir J (2005) 7.58
Standardisation of the measurement of lung volumes. Eur Respir J (2005) 7.48
Six minute walking distance in healthy elderly subjects. Eur Respir J (1999) 3.56
Recommendations on the use of exercise testing in clinical practice. Eur Respir J (2007) 3.15
Mutations in Cdh23, encoding a new type of cadherin, cause stereocilia disorganization in waltzer, the mouse model for Usher syndrome type 1D. Nat Genet (2001) 2.95
Muscle force during an acute exacerbation in hospitalised patients with COPD and its relationship with CXCL8 and IGF-I. Thorax (2003) 2.68
Remediastinoscopy after neoadjuvant therapy for non-small cell lung cancer. Lung Cancer (2002) 2.68
Regulation of mucociliary clearance in health and disease. Eur Respir J (1999) 2.43
Training with inspiratory pressure support in patients with severe COPD. Eur Respir J (2006) 2.18
Airway smooth muscle dynamics: a common pathway of airway obstruction in asthma. Eur Respir J (2007) 2.16
Short- and long-term effects of outpatient rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Am J Med (2000) 1.89
Quantifying physical activity in daily life with questionnaires and motion sensors in COPD. Eur Respir J (2006) 1.77
Airway hyperresponsiveness in asthma: not just a matter of airway inflammation. Thorax (1998) 1.72
Skeletal muscle weakness in patients with sarcoidosis and its relationship with exercise intolerance and reduced health status. Thorax (2005) 1.71
Muscle weakness is related to utilization of health care resources in COPD patients. Eur Respir J (1997) 1.63
Exercise training after lung transplantation improves participation in daily activity: a randomized controlled trial. Am J Transplant (2012) 1.62
Interleukin 8 (IL-8) in the bronchoalveolar lavage fluid from patients with the adult respiratory distress syndrome (ARDS) and patients at risk for ARDS. Cytokine (1992) 1.58
Management of obstructive sleep apnea in Europe. Sleep Med (2010) 1.56
Rehabilitation and acute exacerbations. Eur Respir J (2011) 1.53
Lung function and bronchodilator response in 4-year-old children with different wheezing phenotypes. Eur Respir J (2009) 1.49
Spherocytosis and pulmonary hypertension coincidental occurrence or causal relationship? Eur Respir J (1991) 1.43
The inhalation device influences lung deposition and bronchodilating effect of terbutaline. Am J Respir Crit Care Med (1996) 1.39
Genomic structure, alternative splice forms and normal and mutant alleles of cadherin 23 (Cdh23). Gene (2001) 1.33
Therapeutic electrical stimulation of the hypoglossal nerve in obstructive sleep apnea. Arch Otolaryngol Head Neck Surg (2001) 1.32
Pharmacokinetics and pharmacodynamics of tiotropium solution and tiotropium powder in chronic obstructive pulmonary disease. J Clin Pharmacol (2013) 1.26
Increased prevalence of sleep disturbances and daytime sleepiness in subjects with bronchial asthma: a population study of young adults in three European countries. Eur Respir J (1996) 1.25
Flow analyses in the lower airways: patient-specific model and boundary conditions. Med Eng Phys (2007) 1.22
Resistance versus endurance training in patients with COPD and peripheral muscle weakness. Eur Respir J (2002) 1.19
Primary care spirometry. Eur Respir J (2008) 1.18
Effects of controlled inspiratory muscle training in patients with COPD: a meta-analysis. Eur Respir J (2002) 1.15
Public health and medicolegal implications of sleep apnoea. Eur Respir J (2002) 1.14
Skeletal muscle weakness, exercise tolerance and physical activity in adults with cystic fibrosis. Eur Respir J (2008) 1.13
Validation of two activity monitors in patients with COPD. Thorax (2009) 1.13
Onset and duration of action of single doses of formoterol inhaled via Turbuhaler. Respir Med (1998) 1.12
The European Sleep Apnoea Database (ESADA): report from 22 European sleep laboratories. Eur Respir J (2011) 1.11
Prevalence of sleep disturbances among young adults in three European countries. Sleep (1995) 1.11
Forkhead box M1B is a determinant of rat susceptibility to hepatocarcinogenesis and sustains ERK activity in human HCC. Gut (2009) 1.09
Computational fluid dynamics can detect changes in airway resistance in asthmatics after acute bronchodilation. J Biomech (2007) 1.07
Exercise training in COPD: how to distinguish responders from nonresponders. J Cardiopulm Rehabil (2001) 1.05
A clinical practice guideline for physiotherapists treating patients with chronic obstructive pulmonary disease based on a systematic review of available evidence. Clin Rehabil (2009) 1.05
Indacaterol, a novel inhaled beta2-agonist, provides sustained 24-h bronchodilation in asthma. Eur Respir J (2007) 1.05
Markers of inflammation and disuse in vastus lateralis of chronic obstructive pulmonary disease patients. Eur J Clin Invest (2007) 1.04
On the functional consequences of bronchial basement membrane thickening. J Appl Physiol (1985) (2001) 1.04
Correlation between severity of sleep apnea and upper airway morphology based on advanced anatomical and functional imaging. J Biomech (2006) 1.02
Definition of COPD: based on evidence or opinion? Eur Respir J (2008) 1.01
Assessment of respiratory effort by means of strain gauges and esophageal pressure swings: a comparative study. Sleep (1997) 1.00
The effects of long-term noninvasive ventilation in hypercapnic COPD patients: a randomized controlled pilot study. Int J Chron Obstruct Pulmon Dis (2011) 1.00
Cardiovascular mechanisms and consequences of obstructive sleep apnoea. Acta Clin Belg (2013) 0.98
Vital capacities in acute and chronic airway obstruction: dependence on flow and volume histories. Eur Respir J (1997) 0.98
Respiratory dynamics during laughter. J Appl Physiol (1985) (2001) 0.97
Daytime sleepiness, snoring and gastro-oesophageal reflux amongst young adults in three European countries. J Intern Med (1995) 0.97
Airway responsiveness to methacholine: effects of deep inhalations and airway inflammation. J Appl Physiol (1985) (1999) 0.96
Sodium and potassium channels in demyelinated and remyelinated mammalian nerve. Nature (1981) 0.95
Characteristics of patients with allergic polysensitization: the POLISMAIL study. Eur Ann Allergy Clin Immunol (2008) 0.95
Exercise training and pulmonary rehabilitation: new insights and remaining challenges. Eur Respir Rev (2010) 0.95
Mechanisms for isolated volume response to a bronchodilator in patients with COPD. J Appl Physiol (1985) (2000) 0.94
Massive cerebral infarction after completion pneumonectomy for pulmonary torsion. Thorax (1994) 0.93
Measurement of pulmonary resistance and dynamic compliance with airway obstruction. J Appl Physiol (1985) (1998) 0.93
Cyclosporine treatment of acquired hemophilia due to factor VIII antibodies. Haematologica (2000) 0.92
Effects of drugs on mucus clearance. Eur Respir J (1999) 0.92
Interleukin-8 production in patients undergoing cardiopulmonary bypass. The influence of pretreatment with methylprednisolone. Am Rev Respir Dis (1993) 0.90
Sublingual immunotherapy in polysensitized patients: effect on quality of life. J Investig Allergol Clin Immunol (2010) 0.89
Epidemiology and outcome of invasive pneumococcal disease among adults in Belgium, 2009-2011. Euro Surveill (2014) 0.89
Neck and abdominal muscle activity in patients with severe thoracic scoliosis. Am J Respir Crit Care Med (1998) 0.88
Skeletal muscle force and functional exercise tolerance before and after lung transplantation: a cohort study. Am J Transplant (2008) 0.88
Cardiopulmonary stress during exercise training in patients with COPD. Eur Respir J (2006) 0.87
Is sleep-disordered breathing an additional risk factor for the metabolic syndrome in obese children and adolescents? Int J Obes (Lond) (2008) 0.87
Influence of genetic ancestry on the risk of obstructive sleep apnoea syndrome. Eur Respir J (2010) 0.87
Accuracy of office spirometry performed by trained primary-care physicians using the MIR Spirobank hand-held spirometer. Respiration (2012) 0.86
Quality control of spirometry: a lesson from the BRONCUS trial. Eur Respir J (2005) 0.86
Respiratory and leg muscles perceived exertion during exercise at altitude. Respir Physiol Neurobiol (2011) 0.86
Mechanical energy estimation during walking: validity and sensitivity in typical gait and in children with cerebral palsy. Gait Posture (2011) 0.84
Influence of longterm CPAP therapy on CO(2) drive in patients with obstructive sleep apnea. Respir Physiol (2000) 0.84
Almitrine has no effect on gas exchange after bilateral carotid body resection in severe chronic airflow obstruction. Bull Eur Physiopathol Respir (1986) 0.84
Determinants of physical activity in daily life in candidates for lung transplantation. Respir Med (2012) 0.83
Effect of treatments on the progression of COPD: report of a workshop held in Leuven, 11-12 March 2004. Thorax (2005) 0.83
Age-related changes in mechanical and metabolic energy during typical gait. Gait Posture (2010) 0.83
Hysteresis of airways and lung parenchyma. Respir Med (1995) 0.82
Chronic CO2 drive in patients with obstructive sleep apnea and effect of CPAP. Respir Physiol (1995) 0.82
Variability in lung deposition of inhaled drug, within and between asthmatic patients, with a pMDI and a dry powder inhaler, Turbuhaler. Int J Pharm (2000) 0.82
Medico-legal implications of sleep apnoea syndrome: driving license regulations in Europe. Sleep Med (2007) 0.82
Oxidatively modified proteins in bronchoalveolar lavage fluid of patients with ARDS and patients at-risk for ARDS. Eur Respir J (1999) 0.82
Chemical composition and antimicrobial activity of essential oil of Piper angustifolium. Planta Med (1996) 0.82
Repeat mediastinoscopy in the staging of lung cancer. Eur J Cardiothorac Surg (1998) 0.81
Short- and long-term recovery of upper limb function after axillary lymph node dissection. Eur J Cancer Care (Engl) (2011) 0.81
Lung elastic recoil during breathing at increased lung volume. J Appl Physiol (1985) (1999) 0.81
Relationship between quasi-static pulmonary hysteresis and maximal airway narrowing in humans. J Appl Physiol (1985) (1992) 0.81
High levels of leukaemia inhibitory factor in ARDS. Cytokine (1996) 0.81
Pulmonary haematoma caused by oral anticoagulant therapy. Report of a case. Acta Radiol Diagn (Stockh) (1983) 0.81
Low load inspiratory muscle training increases diaphragmatic fiber dimensions in rats. Am J Respir Crit Care Med (1998) 0.81
Inspiratory muscle training: where are we? Eur Respir J (1994) 0.81
Evaluation for sleep apnea in patients with Ehlers-Danlos syndrome and Marfan: a questionnaire study. Clin Genet (2001) 0.81
Acute effects of inspiratory pressure support during exercise in patients with COPD. Eur Respir J (2004) 0.80
Bronchodilator testing: an endless story. Eur Respir J (2010) 0.80
Intermittent positive airway pressure by nasal mask as a treatment for respiratory insufficiency in a patient with syringomyelia. Respiration (2002) 0.79
Measurement validity of an electronic inspiratory loading device during a loaded breathing task in patients with COPD. Respir Med (2013) 0.79
Purification and characterization of a protective antigen from Eimeria tenella. Infect Immun (1991) 0.79
Intermittent inspiratory muscle training induces fiber hypertrophy in rat diaphragm. Am J Respir Crit Care Med (1997) 0.78